Neumora Therapeutics, Inc.
We are a clinical biopharmaceutical company developing therapies that target brain diseases as well as major depression and other neuropsychiatric brain disorders. (Incorporated in Delaware)
We are taking a fundamentally different approach to the way treatments for brain diseases are developed. We have rapidly scaled our therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. We expect to continue to progress the development of our pipeline with the planned initiation of multiple clinical trials across our programs over the next 12 to 18 months, which supports numerous anticipated data readouts.
Our most advanced product candidate, navacaprant (NMRA-140), is a novel once daily oral kappa opioid receptor (KOR) antagonist that is being developed to treat major depressive disorder (MDD), which we believe has the potential to provide significant advantages relative to the standard of care, if approved. We are initiating a pivotal Phase 3 program for navacaprant monotherapy in patients with moderate to severe MDD. We anticipate releasing topline results for the KOASTAL-1 study in the second half of 2024.
Brain diseases collectively represent one of the largest areas of unmet medical need globally, affecting upwards of 1.5 billion patients. Despite the commercial success of historically approved drugs, the markets for many of the most prevalent brain disorders have been dominated by a single class of drugs, such as serotonin-targeting antidepressants for MDD, leaving patients with a high degree of unmet medical need given the lack of diverse treatment options and mechanisms of action. For example, there are currently over 21 million adults in the United States diagnosed with MDD, 85% of whom either do not receive treatment with a pharmacological agent or fail to achieve remission with first-line selective serotonin reuptake inhibitors (SSRI)/serotonin and norepinephrine reuptake inhibitors (SNRI) and thus progress onto second-line treatment with another SSRI/SNRI.
*Note: Revenue and net loss figures are for the 12 months that ended June 30, 2023.
(Neumora Therapeutics, Inc. priced its IPO on Sept. 14, 2023, in sync with the terms in its prospectus: 14.7 million shares – the same number of shares in the prospectus – at $17.00 – the mid-point of its $16.00-to-$18.00 range – to raise $250.07 million. Background: Neumora Therapeutics, Inc. filed its S-1/A dated Sept. 11, 2023, disclosing terms for its IPO: 14.71 million shares (all from the company) at $16.00 to $18.00 to raise $250.07 million.)
(Neumora Therapeutics, Inc. filed its S-1 dated Aug. 25, 2023, without disclosing terms for its IPO. The proceeds are estimated at $100 million. But some Wall Street pros believe that this IPO could raise up to $250 million. The biotech submitted confidential IPO documents to the SEC on Nov. 8, 2021.)
|Industry:||BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)|
|Address||490 Arsenal Way, Suite 200 Watertown, Massachusetts 02472|
|Phone Number||(857) 760-0900|
|View Prospectus:||Neumora Therapeutics, Inc.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-131.66 mil (last 12 months)|
|Price range||$16.00 - $18.00|
|Est. $ Volume||$250.1 mil|
|Manager / Joint Managers||J.P. Morgan/ BofA Securities/ Stifel/ Guggenheim Securities/ RBC Capital Markets/ William Blair|
|Expected To Trade:||9/15/2023|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|